Clarivate Epidemiology’s coverage of membranous nephropathy (MN) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
Clarivate Epidemiology’s coverage of membranous nephropathy comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed prevalence…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key MN patient populations, covering 171 countries and more than 99% of…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key MN patient populations, covering 171 countries and more than 99% of…
Clarivate Epidemiology’s coverage of membranous nephropathy (MN) comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and the prevalence of…
Clarivate Epidemiology’s coverage of membranous nephropathy (MN) comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and the prevalence of…
Clarivate Epidemiology’s coverage of membranous nephropathy (MN) comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and the prevalence of…
Clarivate Epidemiology’s coverage of membranous nephropathy (MN) comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and the prevalence of…
Clarivate Epidemiology’s coverage of membranous nephropathy (MN) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
Clarivate Epidemiology’s coverage of membranous nephropathy (MN) comprises epidemiological estimates of key patient populations in 45 countries. We report both the incidence and prevalence of MN…
Clarivate Epidemiology's coverage of membranous nephropathy comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed…
Clarivate Epidemiology’s coverage of primary immune thrombocytopenic purpura (ITP) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the…
Clarivate Epidemiology’s coverage of primary immune thrombocytopenic purpura (ITP) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the…
Copy/Paste the key inputs from the product brochure, per guidance from Marketing. The axial spondyloarthritis (AxSpA) therapy market includes biologics from two distinct drug classes: tumor…
Migraine, which afflicts approximately 72 million people in the major pharmaceutical markets according to Clarivate epidemiology, is a heterogeneous condition requiring individualized treatment…